Rimonabant Effectively Reduces Visceral Fat in the Obese Patient as Confirmed by Abdominal Computer Tomography (ct) Scan
PARIS, Sept. 19, 2007-The first direct evidence of the effects of Acomplia® (rimonabant) in significantly reducing human visceral fat (the metabolically active fat wrapped around the bodys vital organs in the abdomen, such as liver, pancreas) is being presented today at the 43rd Annual Meeting of the European Association for the Study of Diabetes (EASD).
View next topic View previous topic
You cannot post new topics in this forum You cannot reply to topics in this forum You cannot edit your posts in this forum You cannot delete your posts in this forum You cannot vote in polls in this forum